St. Bernards launches new cancer therapy program

St. Bernards Healthcare has started a targeted cancer therapy program with its first patient, making it the only health system in Northeast Arkansas to offer this type of cancer care.

The therapy, LUTATHERA, helps patients facing a rare cancer diagnosis, known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs). These cancers develop in the stomach, intestines or pancreas, and can be difficult to treat with standard, more traditional cancer therapies. With LUTATHERA, however, patients as young as 12 years old have another treatment option if their tumors carry a specific group of proteins, known as somatostatin receptors (SSTRs), which the therapy targets.

Before starting treatment, patients receive a specialized scan to confirm their cancer has SSTRs. Once underway, LUTATHERA finds and attaches itself to SSTR proteins on the surface of cancer cells. It then enters the cells, delivering a precise dose of radiation directly to the tumor. The radiation travels no more than 3/32 of an inch in tissue and mostly leaves the body naturally within two days. Within 14 days, more than 99% is gone.

“Bringing LUTATHERA to Northeast Arkansas reflects the commitment of this entire team to ensure our patients have local access to the most advanced cancer therapies available today,” said Dr. Hiba Zara Ahmed, Radiation Oncologist with St. Bernards Cancer Center. “This process was a true collaboration, and I’m grateful how so many expert specialists work together, every day, to make it possible.”

St. Bernards works with Novartis Patient Support to help patients access LUTATHERA, including assistance with insurance, prior authorization and financial support options for those who qualify. Referring physicians, meanwhile, can work directly with St. Bernards to identify appropriate candidates and begin the process.